α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.
about
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's diseaseEmerging preclinical pharmacological targets for Parkinson's diseaseStriatal cholinergic interneuron regulation and circuit effectsNicotinic ACh receptors as therapeutic targets in CNS disordersEfficient expression of functional (α6β2)2β3 AChRs in Xenopus oocytes from free subunits using slightly modified α6 subunitsSLEEPLESS is a bifunctional regulator of excitability and cholinergic synaptic transmissionUnderstanding the role α7 nicotinic receptors play in dopamine efflux in nucleus accumbensAnalysis of rare variations reveals roles of amino acid residues in the N-terminal extracellular domain of nicotinic acetylcholine receptor (nAChR) alpha6 subunit in the functional expression of human alpha6*-nAChRs.Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian miceNicotine from cigarette smoking and diet and Parkinson disease: a review.γ-Aminobutyric acid type A receptor inhibition triggers a nicotinic neuroprotective mechanism.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeysNicotine as a potential neuroprotective agent for Parkinson's disease.Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein.Transcriptional regulation by nicotine in dopaminergic neurons.Pharmacologically distinct nicotinic acetylcholine receptors drive efferent-mediated excitation in calyx-bearing vestibular afferentsNicotinic receptor subtype-selective circuit patterns in the subthalamic nucleus.Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function miceNicotine reduces antipsychotic-induced orofacial dyskinesia in rats.Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake.Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditionsConotoxins that confer therapeutic possibilities.Smoking-Relevant Nicotine Concentration Attenuates the Unfolded Protein Response in Dopaminergic Neurons.Effects of chronic low- and high-dose nicotine on cognitive flexibility in C57BL/6J miceα7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesiasNicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal functionα4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's diseaseExploring the nicotinic acetylcholine receptor-associated proteome with iTRAQ and transgenic mice.Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results.Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.Nicotinic receptors regulate the dynamic range of dopamine release in vivoEffects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotine+cocaine self-administration.Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function α6* nAChRs.ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.Genetic Algorithm Managed Peptide Mutant Screening: Optimizing Peptide Ligands for Targeted Receptor Binding.
P2860
Q21131066-B2152B47-EC3E-4008-ACA7-8319D5640179Q26764724-45CEC9FA-924D-450F-B306-BEB4F08EFEA1Q26863113-F7D48FCA-30CD-4815-96C8-EE93C58E5FC3Q28111941-93DE1E65-89D1-435E-B5CC-326413426094Q28541268-F1F2B036-C1EF-497E-820C-6A19FB24264BQ28658136-92B30F8F-9EF6-4271-8046-B1A0FE13FBE9Q30404614-5EE4D655-04D9-4AFB-B2D6-B2C8F967F3ADQ30413058-92E32A0E-AB15-4AF2-BF61-C3CF6B67D565Q30450052-F1BB3151-9F70-4E0E-B951-170CFE59AD54Q33862534-7386A1E9-6173-4DF4-98FC-31B4B4F9A1B1Q34003760-24237EAA-F97D-4142-9BE3-BBB08670899DQ34112026-559B1D6C-BD15-46C5-831A-F1B71F75442EQ34186299-EFCA8F00-DFA7-4BAF-8E1D-F3A71A1A6B60Q34281003-AF1EF432-8F5B-4DB5-9882-8E4EAA4A7E7DQ34598256-F63D2AB7-1517-4379-89AE-6EE69E40AD8AQ34933695-545DD3EF-1477-4374-B43C-96FF8D823A2DQ35117646-3BAC6EAE-FBC0-4FA3-BE9F-BDA9DE63C0FDQ35142884-2C6F69A5-F889-4C02-B635-EBE2088E9513Q35533526-288D3B57-C302-4505-8374-B0750B1BB789Q35776860-07BE6A15-A2ED-4201-822A-7460856EED52Q35974049-37E87847-DB1D-44B6-BFC5-94B18FC1174CQ36042479-ED78CB14-FF02-4116-A566-C94BAC21E015Q36096681-9B0FD787-9F8D-43B2-8DB6-75C0C21E8857Q36432022-87D72D3C-744C-4C34-B37D-4F39CEE147AFQ36442874-9049343E-4EC0-4C0E-8027-9FEB7777C3C2Q36469995-16F59484-6268-4D2E-B258-C2E92FAA78F9Q36781037-2D6EDC2E-5354-4DB4-BEBE-5EE6F5F91971Q36880148-D4A1309D-B118-4AD3-BF28-EBCD5E2F5CA1Q36936920-6C5B9F14-BC42-4067-9C41-F0BAE19C33DAQ36936930-50E78952-4253-47F1-B64E-A1C38C408C9AQ37193201-767F5A6A-3CAB-466A-97BF-138E5088E4EEQ37209730-69A9610B-844E-4855-BA30-46BE730A82AAQ37250387-B5987B9C-87E7-4C8D-AE7D-8616D1522C76Q37358441-6A49D331-49B2-4CB6-9FD0-65D9AE901ED3Q37384621-CA06159F-0F3D-4E97-9CE1-5FEB273A7FEEQ37578311-EF6E1948-7F2A-4E64-A7B7-7931D0D9646FQ37642452-48C5068E-9531-44A2-A849-2F8ACB089BE6Q37692812-14920955-C999-44A1-B421-1334F3304548Q37708588-0C31EA5F-B508-4823-AD32-E80E18396872Q37722751-44E12786-436A-4402-9A81-9A128533A21B
P2860
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
α6β2* and α4β2* nicotinic acet ...... rgets for Parkinson's disease.
@ast
α6β2* and α4β2* nicotinic acet ...... rgets for Parkinson's disease.
@en
type
label
α6β2* and α4β2* nicotinic acet ...... rgets for Parkinson's disease.
@ast
α6β2* and α4β2* nicotinic acet ...... rgets for Parkinson's disease.
@en
prefLabel
α6β2* and α4β2* nicotinic acet ...... rgets for Parkinson's disease.
@ast
α6β2* and α4β2* nicotinic acet ...... rgets for Parkinson's disease.
@en
P2860
P356
P1476
α6β2* and α4β2* nicotinic acet ...... rgets for Parkinson's disease.
@en
P2093
Maryka Quik
Susan Wonnacott
P2860
P304
P356
10.1124/PR.110.003269
P577
2011-12-01T00:00:00Z